Fluocinolone acetonide 0.18-mg implant for treatment of recurrent inflammation due to non-infectious uveitis: a case series of 15 patients
After receiving the 0.18-mg FAi, eyes with uncontrolled NIU-PS had sustained resolution of CME and inflammation with limited need for supplementary steroid drops or injections and minimal steroid class-specific adverse effects; none required incisional IOP-lowering surgery.
Authors
- Anton M. Kolomeyer (ORCID: https://orcid.org/0000-0002-7782-6826)
- Robert A. Sisk (ORCID: https://orcid.org/0000-0003-0328-7927)
- David Eichenbaum (ORCID: https://orcid.org/0000-0003-0654-0668)
- John W. Kitchens
- Daniel F. Kiernan
- David R.P. Almeida (ORCID: https://orcid.org/0000-0002-1742-1683)
Institutions
- Penn Presbyterian Medical Center (US)
- Retina Associates of Kentucky (US)
- Cincinnati Eye Institute (US)
- The Retina Center (US)
- Retina Vitreous Associates of Florida (US)
- Retina Partners (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Journal of Ophthalmic Inflammation and Infection
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1186/s12348-024-00427-9
- Citations
- 1
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 0.54
Funders
- Alimera Sciences